188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment.

Research output: Contribution to journalArticle

Abstract

Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.

Details

Authors
  • Mohamed Altai
  • Helena Wållberg
  • Hadis Honarvar
  • Joanna Strand
  • Anna Orlova
  • Zohreh Varasteh
  • Mattias Sandström
  • John Löfblom
  • Erik Larsson
  • Sven-Erik Strand
  • Mark Lubberink
  • Stefan Ståhl
  • Vladimir Tolmachev
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Radiology, Nuclear Medicine and Medical Imaging
Original languageEnglish
Pages (from-to)1842-1848
JournalJournal of Nuclear Medicine
Volume55
Issue number11
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes